R R

What Is Kevzara?

Kevzara is a prescription interleukin-6 receptor antagonist containing sarilumab. Current labeling includes moderately to severely active rheumatoid arthritis in adults after inadequate response or intolerance to one or more disease-modifying antirheumatic drugs, polymyalgia rheumatica in adults after inadequate corticosteroid response or intolerance to corticosteroid taper, and active polyarticular juvenile idiopathic arthritis in patients weighing at least 63 kg.

Link to This Resource Page

Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.

To display this...

What Is Kevzara?

Kevzara is a prescription interleukin-6 receptor antagonist containing sarilumab. Current labeling includes moderately to severely active rheumatoid arthritis in adults after inadequate response or intolerance to one or more disease-modifying antirheumatic drugs, polymyalgia rheumatica in adults after inadequate corticosteroid response or intolerance to corticosteroid taper, and active polyarticular juvenile idiopathic arthritis in patients weighing at least 63 kg.

read more about kevzara ...

Copy this HTML:

Copy HTML Copied!

How Does Kevzara Work?

Sarilumab binds to soluble and membrane-bound interleukin-6 receptors and inhibits interleukin-6-mediated signaling. This reduces inflammatory signaling associated with rheumatoid arthritis, polymyalgia rheumatica, and polyarticular juvenile idiopathic arthritis.

Who Is Treated With Kevzara?

Kevzara is used in adults with qualifying rheumatoid arthritis or polymyalgia rheumatica and in patients weighing at least 63 kg with active polyarticular juvenile idiopathic arthritis. Treatment does not begin during an active infection, and patients are tested for latent tuberculosis before therapy.

How Is Kevzara Dosed?

The recommended dose for rheumatoid arthritis is 200 mg by subcutaneous injection once every two weeks, alone or with a conventional disease-modifying antirheumatic drug. Polymyalgia rheumatica uses 200 mg every two weeks with a tapering corticosteroid course, with sarilumab monotherapy possible after corticosteroids are stopped. Patients weighing at least 63 kg with polyarticular juvenile idiopathic arthritis receive 200 mg every two weeks by prefilled syringe.

What Serious Risks Are Linked to Kevzara?

Kevzara carries a boxed warning for serious infections that can lead to hospitalization or death. Other serious concerns include neutropenia, thrombocytopenia, elevated liver enzymes, gastrointestinal perforation, hypersensitivity reactions, and immunosuppression. Complete blood counts, liver tests, and lipid measurements are checked during treatment, and live vaccines are avoided.

Frequently Asked Questions About Kevzara

What conditions does Kevzara treat?

Current labeling includes rheumatoid arthritis, polymyalgia rheumatica, and active polyarticular juvenile idiopathic arthritis under specific criteria.

What is the usual Kevzara dose for rheumatoid arthritis?

The recommended dose is 200 mg by subcutaneous injection once every two weeks.

Who can receive Kevzara for polyarticular juvenile idiopathic arthritis?

Current U.S. labeling includes patients with active disease who weigh at least 63 kg.

Does Kevzara have a boxed warning?

Yes. The boxed warning concerns serious infections that can lead to hospitalization or death.

References

Efficacy and Safety of Sarilumab Monotherapy Versus Adalimumab Monotherapy for the Treatment of Patients With Active Rheumatoid Arthritis (MONARCH): A Randomised, Double-Blind, Parallel-Group Phase III Trial. https://pubmed.ncbi.nlm.nih.gov/27856432/. Date Accessed October 7, 2026.

KEVZARA (Sarilumab) Prescribing Information. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=827bc01c-d379-4266-a18c-c7f904b76af3. Date Accessed October 7, 2026.

Sarilumab and Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors. https://pubmed.ncbi.nlm.nih.gov/27860410/. Date Accessed October 7, 2026.

Sarilumab Injection: MedlinePlus Drug Information. https://medlineplus.gov/druginfo/meds/a617032.html. Date Accessed October 7, 2026.

Sarilumab, a Fully Human Monoclonal Antibody Against IL-6Ra in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Efficacy and Safety Results From the Randomised SARIL-RA-MOBILITY Part A Trial. https://pubmed.ncbi.nlm.nih.gov/24297381/. Date Accessed October 7, 2026.